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Rationale. Idiopathic pulmonary ﬁbrosis (IPF) is a progressive ﬁbrotic interstitial lung disease, with high mortality. Currently, the
aetiology and the pathology of IPF are poorly understood, with both innate and adaptive responses previously being implicated in
the disease pathogenesis. Heat shock proteins (Hsp) and antibodies to Hsp in patients with IPF have been suggested as therapeutic
targets and prognostic biomarkers, respectively. We aimed to study the relationship between the expression of Hsp72 and
anti-Hsp72 antibodies in the BAL ﬂuid and serum Aw disease progression in patients with IPF. Methods. A novel indirect
ELISA to measure anti-Hsp72 IgG was developed and together with commercially available ELISAs used to detect Hsp72
IgG, Hsp72 IgGAM, and Hsp72 antigen, in the serum and BALf of a cohort of IPF (n = 107) and other interstitial lung
disease (ILD) patients (n = 66). Immunohistochemistry was used to detect Hsp72 in lung tissue. The cytokine expression
from monocyte-derived macrophages was measured by ELISA. Results. Anti-Hsp72 IgG was detectable in the serum and
BALf of IPF (n = 107) and other ILDs (n = 66). Total immunoglobulin concentrations in the BALf showed an excessive
adaptive response in IPF compared to other ILDs and healthy controls (p = 0 026). Immunohistochemistry detection of C4d
and Hsp72 showed that these antibodies may be targeting high expressing Hsp72 type II alveolar epithelial cells. However,
detection of anti-Hsp72 antibodies in the BALf revealed that increasing concentrations were associated with improved
patient survival (adjusted HR 0.62, 95% CI 0.45-0.85; p = 0 003). In vitro experiments demonstrate that anti-Hsp72
complexes stimulate macrophages to secrete CXCL8 and CCL18. Conclusion. Our results indicate that intrapulmonary
anti-Hsp72 antibodies are associated with improved outcomes in IPF. These may represent natural autoantibodies, and
anti-Hsp72 IgM and IgA may provide a beneﬁcial role in disease pathogenesis, though the mechanism of action for this
has yet to be determined.
1. Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is the most common
interstitial lung disease (ILD) with an estimated prevalence
of 10-60 cases per 100,000 people worldwide [1]. IPF is
characterised by irreversible and progressive ﬁbrosis, with a
speciﬁc histological feature, namely, usual interstitial pneu-
monia (UIP). Compared to other ILDs, IPF has the poorest
prognosis but a highly variable clinical course [2–4]. A mul-
tidisciplinary approach to diagnosis is required, and a
conﬁdent diagnosis may require patients to undergo lung
biopsy. Currently, the mechanisms underpinning disease
progression are poorly understood, but it is thought that an
unidentiﬁed inﬂammatory incident may lead to a continuous
and disruptive immune response with excessive alveolar
epithelial cell (AEC) death and aberrant reepithelisation with
type II AECs [5].
A role for IgG in IPF pathology was originally postulated
when detection of complement activation through the classi-
cal pathway was seen in the pleural space [6] and immune
complexes were shown in the alveolar ﬂuid of IPF patients
[7]. Both humoral and cell-mediated immunity have been
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implicated in the pathogenesis of IPF. Heightened circulating
concentrations of CXCL13 [8] and lung parenchymal prolif-
erative B cell aggregates with dendritic cells forming germinal
centers [9, 10] indicate the presence of an active humoral
response. This has led to the hypothesis that B cells con-
tribute to the pathogenesis UIP and is the rationale for
B cell-targeted therapies in IPF [11]. It has been further
hypothesised that this humoral response may be autoim-
mune in nature. Previous studies have demonstrated that T
cells isolated from IPF patients can proliferate in response
to lung-derived autoantigens indicating a breakdown in
self-tolerance [12–15]. Further to this, it was observed that
CD4+ T cells only proliferated in response to protein samples
prepared from IPF lung tissue and not healthy tissue [15].
Circulating autoreactive IgG, against a 70-90 kDa alveolar
epithelial cell (AEC) antigen, was ﬁrst detected in IPF
patients by Wallace et al. [16, 17]. More recently, circulating
antibodies to Hsp72 were shown to be associated with poorer
outcomes in IPF [14] but have not yet been validated in
independent cohorts. A number of other autoreactive IgG
antibodies have been described that similarly target AEC
antigens including annexin-1 [18] and cytokeratins-8 and
-19 [19, 20], periplakin [21], and vimentin [22] BPIFB1
[23]. Certain autoantibodies detected in IPF have also been
described as having functional eﬀects, with anti-Hsp72 IgG
from IPF patients inducing the secretion of CXCL8 and
expression of CD69 in monocytes [14]. The transfer of auto-
antibodies to BPIFB1 into Rag-/- mice did not result in ILD.
However, the transfer of BPIFB1-speciﬁc CD4+ cells led to
spontaneous ILD induction which was not observed in mice
with intact immune systems [23]. This suggests that a break
in T cell tolerance could lead to the development of ILD.
However, others have suggested that autoantibodies in ILD
may be epiphenomenal [24].
The presence of IgG autoantibodies is generally consid-
ered to represent a breakdown of self-tolerance and is
associated with pathological consequences. Alternatively,
these antibodies may instead represent IgG “natural” autoan-
tibodies that have been described in healthy individuals [25]
and may have a role in maintaining homeostasis. Natural
autoantibodies are recognised as being polyreactive with
low aﬃnities [26] and recognise highly conserved molecules
[27]. In COPD, natural autoantibodies have been seen to
target similar antigens as those previously detected in
IPF, including cytokeratin-18, as well as disease-speciﬁc
autoantibodies such as against collagen 5 [28]. Therefore,
there is some evidence for the presence of natural autoanti-
bodies in ILD. The compartment, circulating versus tissue,
in which these postulated natural IgGs are expressed, may
provide insights into their role. In addition, the presence of
autoantibodies in the serum of IPF patients may provide a
novel means of prognosticating IPF patients. Detection of
anti-Hsp72 [14] and anti-periplakin IgG [21] have been
(independently) linked to poorer outcomes in IPF; however,
anti-Hsp72 IgG has yet to be validated and anti-periplakin
IgG was undetectable in a diﬀerent cohort of IPF patients
[29]. We hypothesise that elevated anti-Hsp72 IgG will asso-
ciate with IPF disease progression and will induce immune
cells to promote a ﬁbrotic response.
2. Methods
2.1. Patient Demographic and Ethical Consent. Ethical
permission was granted from the NHS Lothian Research
ethics board (LREC 07/S1102/20 06/S0703/53). Participants
were incident cases attending the Edinburgh Lung Fibrosis
Clinic. Serum samples were obtained at ﬁrst presentation to
the clinic, and BAL was obtained within the ﬁrst 12 months
of ﬁrst presentation, patient demographics used in this study
are in Table 1. All diagnoses of ILD were made by multi-
disciplinary consensus according to ATS/ERS consensus cri-
teria [30]. “Other ILD” comprises a group of non-IPF ILD
patients with the disease breakdown of 13 patients with
hypersensitivity pneumonitis (HP), 11 patients with idio-
pathic nonspeciﬁc interstitial pneumonia (NSIP), and 42
patients with “unclassiﬁable” disease. “Unclassiﬁable” ILD
refers to disease that (i) was idiopathic, (ii) did not fulﬁl CT
criteria for deﬁnite IPF or possible IPF and have a radiologi-
cal pattern that is compatible but not diagnostic of at least
one of the recognised forms of interstitial pneumonia, and
(iii) is not biopsied. These unclassiﬁable entities are further
divided into those with and without ﬁbrosis based on CT
imaging [4]. Serum and bronchoalveolar lavage (BAL) sam-
ples were taken with permission from 157 ILD patients; IPF
disease progression was deﬁned as a decrease of ≥10% in lung
function as measured by vital capacity (VC) or pulmonary-
related death in the twelve months postsampling [2, 3].
“Control” bronchoalveolar lavage and serum were obtained
from subjects that required bronchoscopy for isolated hae-
moptysis but had no evidence of lung disease based on CT
imaging and are referred to as “healthy controls.”
2.2. Immunoassays. Commercial anti-Hsp72 IgG assays
were not available at the time of study; thus, anti-Hsp72
IgG was measured using an in-house optimised indirect
ELISA, using the ILD patient serum as a source for the
anti-Hsp72 IgG standard. The serum from 5 patients was
pooled to generate the anti-Hsp72 IgG standard and was
determined using the method described below and identiﬁed
by the increased 450nm OD readings measured. To brieﬂy
describe, 100 ng/ml recombinant (r)Hsp72 (SignalChem,
H34-54H) was incubated overnight at 4°C in an ELISA plate.
Between each of the following steps, 3 washes were made
using PBS with 0.1%Tween. ELISA plates were blocked using
RD (R&D DY995, 10x reagent diluent diluted 1 : 10 in PBS).
Patient samples were optimised for the assay; serum samples
were diluted 1 : 1000 and BALf samples 1 : 100 in RD and
incubated for one hour (samples outside the standards were
reanalysed with more appropriate dilutions as required).
Detection of anti-Hsp72 IgG was performed using a biotin-
conjugated anti-human IgG (Vector Laboratories, BA-
3000), incubated for 2 hours. HRP-conjugated streptavidin
(R&D Systems, sourced from other commercial ELISA kits)
was incubated at the appropriate concentrations, and TMB-
HRP reactions were measured using a BioTek Synergy H1
Hybrid Plate Reader.
ELISAs for CXCL8 (DY208), Hsp72 (DY1663), and
CCL18 (DY394) were sourced from R&D (Abingdon, UK).
ELISA for total IgG (88-50550), total IgA (88-50600),
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and total IgM (88-50620) was sourced from Aﬀymetrix
eBioscience (High Wycombe, UK). ELISAs for anti-
Hsp72 IgGAM (ADI-EKS-750) were sourced from Enzo
Life Sciences (Exeter, UK). These ELISAs were used fol-
lowing the manufacturers’ protocol.
2.3. Protein G Isolation of IPF Patient IgG. BALf IgG from 6
IPF patients was puriﬁed using Protein G (Thermo Fisher
Scientiﬁc, #20398). For each patient, 4ml of BALf was diluted
1 : 1 with Protein G binding buﬀer (Thermo Fisher Scientiﬁc,
#21011) and allowed to gravity ﬁlter through Protein G
agarose. Puriﬁed IgG was eluted using 2ml elution buﬀer
(Thermo Fisher Scientiﬁc, #21004), and the pH was stabilised
with 100μl Tris (pH8).
2.4. MDM Cell Culture. PBMCs were isolated from whole
blood using a standard Ficoll-Paque isolation method.Whole
blood was diluted 1 : 1 with sterile PBS. Diluted whole blood
was then layered over Ficoll at a 3 : 1 ratio of volume (3ml
of blood per 1ml of Ficoll). Samples were then centrifuged
at 1500g for 20 minutes without braking. After centrifuga-
tion, cells were collected, washed in PBS, and counted prior
to monocyte isolation.
CD14+/CD16-, CD14-/CD16+, andCD14+/CD16+mono-
cytes were negatively selected from the PBMCs using a
Pan-monocyte isolation kit (Miltenyi Biotec, 130-096-537)
following the manufacturer’s protocol. Isolated monocytes
were diﬀerentiated into MDMs by culturing them for 4 days
in a 96-well culture plate in IMDM supplemented with 10%
FBS, 1% L-glutamine, 100μg/ml penicillin, 100 IU/ml strep-
tomycin, 2% AB serum, and 5ng/ml M-CSF. Following
4 days of culture, MDMs were treated with the following
conditions for 24 hours: untreated, 100 ng/ml Hsp72 (Sino
Biological, 11660-H07B), 1μg/ml and 10μg/ml monomeric
Hsp72 IgG (mouse monoclonal IgG1, Abcam, ab47455),
1μg/ml and 10μg/ml of monomeric isotype IgG1 (Abcam,
ab91353), 1μg/ml and 10μg/ml Hsp72-IgG complex (gener-
ated by incubating the Hsp72 and Hsp72 IgG1 antibody at a
1 : 3 ratio for 20 minutes prior to MDM treatment), 50 ng/ml
LPS, and 1μg/ml IPF patient BALf IgG (with and without
preincubation with 100 ng/ml Hsp72). Cell culture super-
natant was retrieved after 24 hours of MDM cell treatment
for analysis.
2.5. Immunohistochemistry. Immunohistochemistry for Hsp72
and C4d was performed on UIP and chronic HP lung
biopsies. Hsp72 staining was performed by the SURF
Immunohistochemistry using a BOND-MAX Automated
Immunostainer at the QMRI, Little France, Edinburgh.
C4d staining was performed using a BOND-MAX Auto-
mated Immunostainer by NHS Lothian at Edinburgh
Royal Inﬁrmary. Hsp72 staining used a peroxidase-DAB
method, and C4d staining used an alkaline phosphatase
staining method.
2.6. Statistical Analysis. Nonparametric statistical tests were
used where indicated. Kaplan-Meier (KM) survival and a
Cox proportional hazard regression analysis were used for
patient survival analysis, and hazard ratios (HR) adjusted
for patient clinical data were made.
3. Results
3.1. Total IgG Is Elevated in IPF Patient BALf but Decreased
in the Serum Compared to Healthy Controls. IPF is not
considered a classical autoimmune disease; however, it has
been reported that IPF patients express some features of
classical autoimmunity such as elevated CXCL13 expression
[8]. Increased titre of circulating IgG is a feature of classical
autoimmune diseases such as systemic lupus erythematosus
and rheumatoid arthritis [31, 32]. Therefore, we measured
total IgG and IgA in the serum and BAL ﬂuid (BALf) of a
cohort of IPF patients; non-IPF ILD patients, henceforth
referred to as “other ILD”; and healthy controls. IPF patients
were found to have elevated IgG compared to both other ILD
patients and healthy controls (Figure 1(a), p = <0 0001). Both
IPF and other ILD patients had elevated serum IgA com-
pared to healthy controls (Figure 1(b), p = 0 016). In the
IPF cohort, patients can be split into “progressor” and
Table 1: Patient demographics.
All IPF patients
(n = 107)∗
IPF progressors
(n = 30)
IPF nonprogressors
(n = 52)
Other ILDs
(n = 66)
Healthy controls
(n = 19)
Sex (% male) 73.8 83.3 67.3 57.6 42.1
Median age at BAL (+range) 73 (51-87) 71.5 (51-85) 73 (57-85) 64 (41-81) 66 (44-70)
BAL tested (%) 63.6 76.7 71.1 56 36.8
BAL baseline % predicted vital capacity (VC)
mean ± SEM 89 7 ± 2 7 83 5 ± 4 5 92 4 ± 3 3 88 7 ± 3 1 99 3 ± 5 3
BAL baseline % predicted TLCO mean ± SEM 53 8 ± 1 8 51 0 ± 2 7 55 5 ± 2 3 57 0 ± 2 4 n/a
Median age at serum (+range) 74 (51-89) 74 (51-89) 74 (52-87) 65 (31-85) 66 (44-87)
Serum tested (%) 76.6 93.3 94.2 78.8 79.0
Serum baseline % predicted vital capacity (VC)
mean ± SEM 86 4 ± 2 4 79 7 ± 3 7 90 2 ± 3 1 87 1 ± 2 8 99 3 ± 5 3
Serum baseline % predicted TLCO mean ± SEM 53 4 ± 1 8 46 1 ± 3 4 49 1 ± 1 9 57 6 ± 2 2 n/a
∗At the time of analysis, 25 of the 107 IPF subjects had not been followed up for at least 12 months; hence, there are 30 progressors, 52 nonprogressors,
and 25 not determined at the time of analysis.
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“nonprogressor” subgroups, with IPF progression deﬁned as
≥10% loss in VC or IPF-related death within 12 months of
sampling. When the IPF cohort was split into these two
subgroups, it was found that IPF progressors had an ele-
vated concentration of serum IgG (p = 0 043). Conversely,
in the BALf, elevated concentrations of IgG and IgA were
found in IPF patients compared to healthy controls
(Figures 1(c) and 1(d), IgG p = <0 0001, IgA p = 0 026).
IPF patients were also found to have elevated IgG, but
not IgA, compared to other ILDs. When comparing IPF
patient subgroups, no diﬀerences were found in the BALf
immunoglobulin concentrations.
3.2. The Distribution of Hsp72 Expression in IPF. Previous
work has demonstrated the presence of anti-Hsp72 antibod-
ies in IPF patients [14]; therefore, we measured concentra-
tions of the target antigen in the serum and BALf of ILD
patients and healthy controls (Figures 2(a) and 2(b)).
Hsp72 was found to be elevated in the serum of IPF and other
ILD patients compared to controls (Figure 2(a) p = 0 002),
with no diﬀerence between ILD patient subgroups. Hsp72
concentrations measured in the BALf were not signiﬁ-
cantly diﬀerent between ILD patients and healthy controls
(Figure 2(b)).
Lung biopsies of 8 IPF patients showed high expression
of Hsp72 in type II hyperplastic AECs near ﬁbrotic foci
(Figure 2(d)). Hsp72 was detectable in all samples but varied
between patients. Hsp72 expression was also detected in
bronchial cells, immune cells (macrophage and lymphoid
cells), and the extracellular compartment.
C4d is a downstream product of the IgG-activated
complement classical pathway and has previously been used
as a marker of antibody-mediated rejection in transplants
[33]. Therefore, detection of C4d deposition can be used to
indicate the presence of IgG. We found a similar pattern of
detection of C4d compared to Hsp72 in the IPF patient lung
biopsies. This may therefore suggest the presence of anti-
Hsp72 antibodies in IPF patient lungs.
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Figure 1: Total IgG and IgA concentrations in the serum and BALf were elevated in IPF. Total IgG was found to be signiﬁcantly elevated in
the serum of IPF patients compared to other ILD patients and healthy controls ((a) p = <0 05). IPF and other ILD patients had elevated IgA
compared to healthy controls ((b) p = 0 016). BALf concentrations of IgG were elevated in IPF compared to other ILDs and healthy controls
((c) p = <0 001 and p = <0 0001, respectively; other ILDs to healthy controls not signiﬁcant by Kruskal-Wallis). BALf concentrations of IgA
were elevated in IPF compared to healthy controls ((d) p = 0 026; other ILDs to healthy controls not signiﬁcant by Kruskal-Wallis). IPF
progressors had elevated serum IgG compared to nonprogressors (p = 0 043). No diﬀerences were seen between IPF subgroups in serum
IgA or BALf IgG or IgA. Statistical analysis between patient cohorts and healthy controls was performed using the Kruskal-Wallis test
with Dunn’s posttest. Comparison between IPF progressors and nonprogressors was analysed with the Mann-Whitney U test.
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3.3. Decreased BALf Anti-Hsp72 IgG and IgGAM Is
Associated with Disease Progression. To test whether
increased anti-Hsp72 antibody expression could be a deter-
mining factor in IPF progression, we measured anti-Hsp72
IgG concentrations in the serum and BALf using both an
in-house optimised ELISA and a commercially available
anti-Hsp72 IgGAM ELISA (Figure 3). No signiﬁcant diﬀer-
ence was observed between IPF patients, other ILD patients,
and healthy controls in anti-Hsp72 IgG serum concentra-
tions (Figure 3(a), p = 0 72) or anti-Hsp72 IgGAM concen-
trations (Figure 3(b), p = 0 24). There was no diﬀerence in
anti-Hsp72 IgG or IgGAM serum concentrations when
patients were split into progressors and nonprogressors
(Figures 3(a) and 3(b)).
No signiﬁcant diﬀerence was observed in BALf anti-
Hsp72 IgG between IPF and other ILD patients (Figure 3(c),
p = 0 084). Anti-Hsp72 IgGAM was not measured in other
ILD patient serum and BALf. We observed signiﬁcantly
lower concentrations of anti-Hsp72 IgG (Figure 3(c), p =
0 014) and anti-Hsp72 IgGAM (Figure 3(d), p = 0 005) in
IPF progressors compared to nonprogressors.
3.4. Increased Concentrations of BALf Anti-Hsp72 IgGAM,
but Not Anti-Hsp72 IgG, Are Associated with Increased
Patient Survival. Antibody concentrations did not associate
with disease severity (as measured by patient percentage
predicted VC and TLCO values, supplementary Figure 1).
However, anti-Hsp72 antibodies in the BALf were elevated
IPF patients who were nonprogressors compared to
progressors. We analysed the association between BALf
anti-Hsp72 antibody (and total IgG and IgA) concentrations
and patient survival.
Patients were dichotomised into high expressing and low
expressing patients according to the median value to generate
a Kaplan-Meier (KM) survival curve (Figure 4). In the unad-
justed model, lower concentrations of IgA but higher concen-
trations of anti-Hsp72 IgGAM were found to associate with
increased patient survival (Figure 4; IgA HR=2.085, p =
0 048; anti-Hsp72 IgGAM HR=0.44, p = 0 018).
Using a Cox proportional hazard model, and after
adjusting for age, sex, smoking status, percentage-predicted
VC, and percentage-predicted TLCO, no signiﬁcant associa-
tion was identiﬁed for total BALf IgA and survival but
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Figure 2: Elevated expression of Hsp72 in IPF patients occurred in lung epithelia and coincided with C4d deposition. IPF patient serum and
BALf was measured for Hsp72 using a commercial ELISA (IPF n = 82, other ILDs n = 38, healthy controls n = 22). Serum concentrations of
Hsp72 were elevated in ILD patients compared to healthy controls ((a) p = 0 002). Hsp72 concentrations in the BALf were normalised to total
albumin content, and no diﬀerence was seen between ILD and healthy controls ((b) p = 0 059). Immunohistochemistry detection of Hsp72
and C4d was performed on 8 IPF biopsies with UIP ((c) unstained control, (d) Hsp72 detection, and (e) C4d detection). Detection of
Hsp72 and C4d was seen in hyperplastic alveolar epithelia (denoted by blue arrows) near areas of ﬁbrotic foci (FF). Statistics was
performed using a Kruskal-Wallis test with Dunn’s posttest.
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increased BALf anti-Hsp72 IgGAM was associated with
improved patient survival (adjusted HR 0.62, 95% CI
0.45-0.85; p = 0 003).
3.5. MDM Response to Hsp72-IgG Complexes. Hypothesising
that increased survival through anti-Hsp72 antibodies is
mediated by immune cells, we isolated IgG from the BALf
of IPF patients and cultured the IgG on MDMs with or with-
out prior coincubation of IgG with Hsp72 (Figure 5). MDMs
secreted CXCL8 when induced with IPF patient BALf IgG
coincubated with 100ng/ml Hsp72 (Figure 5(a), p = 0 031).
CCL18 secretion had no changes when cultured with IPF
patient BALf IgG with and without Hsp72; under both
conditions, there was a 4-fold increase in CCL18 secretion
compared to untreated cells (Figure 5(b)).
4. Discussion
The role of autoimmunity and speciﬁcally immunoglobu-
lins, in the pathogenesis of IPF, is unclear. Our initial
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Figure 3: Anti-Hsp72 IgG and IgGAM concentrations are elevated in the BALf of IPF patient nonprogressors compared to progressors.
Anti-Hsp72 IgG was measured in the serum and BALf using the in-house optimised anti-Hsp72 IgG ELISA and commercial anti-Hsp72
IgGAM ELISA (IPF n = 82, other ILDs n = 46, healthy controls n = 17). BALf concentrations of anti-Hsp72 IgG and IgGAM are
standardised to BALf total IgG. Between ILD subgroups and healthy controls, no signiﬁcant diﬀerence was seen in the serum anti-Hsp72
IgG ((a) p = 0 72) or anti-Hsp72 IgGAM ((b) p = 0 24). No signiﬁcant diﬀerence was seen between IPF progressor and nonprogressor
patient serum anti-Hsp72 IgG ((a) p = 0 83) or serum anti-Hsp72 IgGAM ((b) p = 0 95) concentrations. Elevated concentrations of BALf
anti-Hsp72 IgG ((c) p = 0 014) and anti-Hsp72 IgGAM ((d) p = 0 005) were seen in IPF nonprogressors compared to progressors.
Statistical analysis was performed using Kruskal-Wallis with Dunn’s posttest and Mann-Whitney U tests.
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observations focussed on total immunoglobulin concentra-
tions as increased titres of circulating IgG are normally
reported in classical autoimmune diseases such as systemic
lupus erythematosus and rheumatoid arthritis [31, 32]. In
this study, we found that BALf IgG (and IgM, supplementary
Figure 3) levels were signiﬁcantly elevated in IPF patients
compared with other ILDs, which in turn were higher than
controls (signiﬁcantly higher with respect to IgG and a
trend seen with IgA and IgM). BALf IgA was seen to be
signiﬁcantly elevated in IPF with respect to controls but
comparable to other ILDs. In the serum, only IgG, but not
IgA or IgM, levels were higher in IPF versus other ILD
patients. These data suggest a heightened humoral response
in the lungs of IPF patients compared to other ILD
patients, which is consistent with previous observations of
organised B cells in IPF lungs [9, 10]. Elevated serum IgG
can be associated with autoimmune disorders such as
rheumatoid arthritis, and so, this IgG response in IPF could
be due to the loss of self-tolerance seen in IPF [12–15].
Indeed, the presence of various autoantibodies supports this
hypothesis [14, 18–23].
Having found supporting evidence for a potential auto-
immune process in IPF, we sought to investigate anti-
Hsp72 antibodies in our patients. Various autoantibodies
have been described in IPF [18–23], but our group has in
the past described putative Hsp72 autoantigen expression
in IPF [16, 17], and others have shown circulating anti-
Hsp72 antibody to be associated with poor outcome in IPF
[14] We therefore initially hypothesised that anti-Hsp72
IgG would be elevated in the serum and BAL and associate
with disease progression and poorer survival. However, we
found that serum anti-Hsp72 antibodies were similar in the
IPF progressor versus nonprogressors and indeed no diﬀer-
ent to patients with other ILDs and controls. These results
seem to contradict previous ﬁndings [14]. However, a crucial
methodological diﬀerence in the detection of anti-Hsp72 IgG
may be responsible for this discrepancy; we assayed anti-
Hsp72 IgG targeted to rHsp72 in native form, and Kahloon
Pe
rc
en
t s
ur
vi
va
l
100
80
60
40
20
0
0 500 1000 1500
Survival (days)
2000 2500 3000
High IgG
Low IgG
(a)
Pe
rc
en
t s
ur
vi
va
l
100
80
60
40
20
0
0 500 1000 1500 2000 2500 3000
Survival (days)
High IgA
Low IgA
(b)
Survival (days)
High anti-Hsp72 IgG
Low anti-Hsp72 IgG
Pe
rc
en
t s
ur
vi
va
l
100
80
60
40
20
0
0 500 1000 1500 2000 2500 3000
(c)
Survival (days)
High anti-Hsp72 IgGAM
Low anti-Hsp72 IgGAM
Pe
rc
en
t s
ur
vi
va
l
100
80
60
40
20
0
0 500 1000 1500 2000 2500 3000
(d)
Figure 4: IPF patients with raised concentrations of BALf anti-Hsp72 IgGAM have longer survival rates. Total BALf IgG, IgA and anti-Hsp72
IgG IgGAM were split between high (red lines) and low (black lines) expression rates by the median value. A Kaplan-Meier survival
curve from the date of the BAL sample was made to either death or the census date. No association with survival was seen in total
IgG ((a) HR 0.82, 95% CI 0.45-1.49, p = 0 51) or anti-Hsp72 IgG ((c) HR 1.38, 95% CI 0.50-1.74, p = 0 33). Total IgA ((b) HR 2.09,
95% CI 1.01-4.32, p = 0 048) and anti-Hsp72 IgGAM ((d) HR 0.44, 95% CI 0.20-0.92, p = 0 018) associated with improved patient
survival. Total IgA and anti-Hsp72 IgGAM were reanalysed using a Cox proportional hazard model adjusting for age, sex, smoking, and
percentage predicted VC and TLCO. After adjustment, total IgA showed no association with patient survival (adjusted HR 0.85, p = 0 77),
whilst elevated anti-Hsp72 IgGAM did show a signiﬁcant association with survival (adjusted HR 0.62, 95% CI 0.45-0.85, p = 0 003).
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et al. found that detection using nondenatured rHsp72 had
no associations to clinical outcomes [14]. Furthermore, and
contrary to our hypothesis, we found higher levels of anti-
Hsp72 IgG and IgGAM in the BALf in IPF nonprogressors
compared to progressors, and for Hsp72 IgGAM, higher
BALf expression was associated with increased survival in
an adjusted multivariate analysis model.
Given these data, we speculate that Hsp72 antibodies
are natural in origin in IPF. Hsp72 ﬁts the archetypal role
of a natural autoantibody antigen. Natural autoantibodies
are hypothesised to mediate immune responses typically,
though not exclusively through autoreactive IgM, with
anti-leukocyte IgM regulating innate and adaptive immune
mechanisms (reviewed by Lobo et al. [34]). It has been
observed that the presence of anti-dsDNA IgM may reduce
the severity of lupus nephritis in SLE patients [35]. However,
in our studies, total IgM did not associate with ILD disease
or with IPF patient survival (Supplementary Figure 3).
Natural autoreactive IgG has also been demonstrated to
have a mediating role in inﬂammation in other disease
models [36, 37]. We observed no association of total BALf
immunoglobulin with IPF outcomes; however, the presence
of various antibodies in IPF including Hsp72 [18–22, 38]
supports the possibility of antigen-speciﬁc natural antibodies
modulating disease pathogenesis and impacting patient
outcomes.
The provenance of anti-Hsp72 antibodies in the lungs of
IPF patients is uncertain. We speculate that anti-Hsp72
immunoglobulins in the lung are natural, as they are
detectable in healthy controls, but we cannot rule out that
the pulmonary antibodies in particular do not arise until
after disease onset. The establishment of organised and
proliferative B cell germinal centers in IPF lungs [9, 10] and
the elevation of immunoglobulins seen in the BALf in this
study support a reactive process. It may be possible that the
lung expression of anti-Hsp72 IgG arises due to the impair-
ment of TReg lymphocytes [13]. The presence of serum
anti-Hsp72 IgG may be due to leakage from the diseased
lung, but no correlation between the serum and BALf IgG
or anti-Hsp72 IgG was seen (data not shown).
Macrophages are reportedly activated in IPF [10, 39, 40],
and as they express a suite of Fcγ receptors, it seems highly
likely they would be cardinal cells to respond to a functional
antibody in IPF. We found that MDMs treated with IgG
isolated from patient BALf secreted more CXCL8 when
exposed to Hsp72 than those cells treated with the IgG
alone. This was also true using commercial anti-Hsp72-
derived antibodies (supplementary Figure 4). Macrophages
have previously been suggested to be a major source of
CCL18 in IPF [40], which our data also supports and
shows this may be due to IgG stimulation of macrophages.
Polymorphisms in FcγRIIa and FcγRIIIb in IPF patients
may alter macrophage responses [41, 42]. Further work is
required to fully determine the repertoire of antibodies in
IPF and their functional relevance to macrophages and
other FcγR expressing cells, such as neutrophils.
The focus of autoimmunity in IPF, often targeting epithe-
lial antigens, has conventionally been hypothesised as being
pathological in nature. Here, we report that elevated serum
IgG is a feature of IPF, in keeping with other classical autoim-
mune diseases. However, the intrapulmonary autoantibody
to Hsp72 may have a protective role. We speculate that
anti-Hsp72 IgG is natural in origin and promotes a homeo-
static immune response.
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Figure 5: Hsp72-IgG complexes induce CXCL8 secretion from in vitro MDM culture. MDM cell culture supernatant was analysed for
CXCL8 (a) and CCL18 (b) by ELISA after treatment with 1 μg/ml IgG isolated from BALf of IPF patients ± 100 ng/ml Hsp72 (IPF
patient n = 6, repeated twice) for 24 hours. 1 μg/ml of BALf IgG did not lead to any overt fold change in CXCL8 secretion in comparison
to untreated cells, but preincubation of IgG with Hsp72 led to increased CXCL8 secretion ((a), p = 0 031). A 4-fold increase in MDM
CCL18 secretion was seen in response to BALf IgG, with Hsp72 preincubation having no eﬀect ((b), p = 0 84). Statistical tests to compare
BALf IgG with preincubated BALf IgG used a Wilcoxon test; no statistical comparison was made with untreated cells.
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Supplementary Materials
Supplementary 1. Supplementary Table 1: shows the break-
down of the 3 groups of patients who constituted the “other
ILD” patient group used for analysis in this study.
Supplementary 2. Supplementary Figure 1: the concentra-
tions of serum and BALf anti-Hsp72 IgG and IgGAM did
not correlate with decreased percentage predicted values of
VC or TLCO. BALf anti-Hsp72 antibody concentrations are
not a marker of disease severity in IPF. BALf anti-Hsp72
IgG (a, b) and IgGAM (c, d) concentrations were correlated
against the percentage predictive values of VC and TLCO in
IPF patients. Correlations were performed using a Spearman
rank. BALf Anti-Hsp72 IgG concentrations were standar-
dised to BALf total IgG concentrations. BALf anti-Hsp72
IgG had no correlation with VC ((a) r = 0 083, p = 0 54) or
TLCO ((b) r = −0 058, p = 0 69). BALf anti-Hsp72 IgGAM
had no correlation to VC ((c) r = 0 11, p = 0 40) or TLCO
((d) r = 0 13, p = 0 35).
Supplementary 3. Supplementary Figure 2: BALf anti-Hsp72
IgG normalised to total protein is elevated in IPF compared
to healthy controls. BALf anti-Hsp72 IgG was normalised
to total protein concentrations measured by BCA. IPF
progressors (p = <0 001) and nonprogressors (p = <0 0001)
were elevated compared to healthy controls, and nonprogres-
sors had elevated concentrations compared to other ILDs
(p = <0 0001). A nonsigniﬁcant elevation in anti-Hsp72 IgG
was seen in nonprogressors compared to progressors
(p = 0 096).
Supplementary 4. Supplementary Figure 3: serum IgM had no
diﬀerence between all ILD patients and healthy controls
(p = 0 30). BALf IgM was signiﬁcantly elevated in IPF
patients compared to other ILD patients (p = 0 003). Serum
((b) HR=1.03, 95% CI 0.58-1.82) and BALf ((d) HR 0.99,
95% CI 0.49-2.02) IgM levels were not associated with IPF
patient outcomes or survival.
Supplementary 5. Supplementary Figure 4: Hsp72-IgG
complexes induce CXCL8 secretion from in vitro MDM
culture. MDM cell culture supernatant was analysed for
CXCL8 (a, c) and CCL18 (b, d) by ELISA after treatment with
100 ng/ml Hsp72, 1μg/ml anti-Hsp72 IgG, 1μg/ml Hsp72-
IgG complex, or 50 ng/ml LPS ((a, b) n = 7) for 24 hours.
Elevated CXCL8 secretion was seen in response to 10μg/ml
mouse monomeric Hsp72 IgG and Hsp72-IgG complexes
((a) p = <0 05 and p = <0 001, respectively). No secretion
of CCL18 was seen in response to mouse anti-Hps72 IgG
((b) p = 0 24, LPS excluded). (c) and (d) show the measured
concentrations of CXCL8 and CCL18 after MDM culture
with 1μg/ml isolated BALf IgG with and without preculture
with 100ng/ml Hsp72. A signiﬁcant diﬀerence was observed
in CXCL8 ((c) p = 0 012) and CCL18 ((d) p = 0 032) secre-
tion; however, poststats failed to identify the diﬀerence
which is likely due to the experiment being underpowered.
CXCL8 secretion was induced by BALf IgG preincubated
with 100ng/ml Hsp72 in a nonsigniﬁcant trend compared
to BALf IgG alone ((c) p = 0 063).
Supplementary 6. Supplementary Figure 5: the in-house
optimised and commercial ELISA had a correlation in anti-
Hsp72 antibody detection in the BALf. Serum concentrations
of anti-Hsp72 antibodies did not correlate between the two
ELISAs ((a) p = 0 24, Spearman r = 0 16). BALf concentra-
tions were used normalised to total IgG as nonnormalised
data for anti-Hsp72 IgGAM is unavailable. BALf concentra-
tions of anti-Hsp72 antibodies correlated between ELISAs
((b) p = 0 0009, Spearman r = 0 48). Anti-Hsp72 IgG con-
centrations not normalised to total IgG had a near signiﬁcant
correlation with total IgG normalised anti-Hsp72 IgGAM
concentrations (not shown, p = 0 051, Spearman r = 0 30).
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